⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5146601 | 0.78 | — | — | |
| SCHEMBL27610488 | 0.77 | — | — | |
| SCHEMBL967609 | 0.72 | — | — | |
| SCHEMBL1345887 | 0.72 | — | — | |
| SCHEMBL966587 | 0.71 | — | — | |
| SCHEMBL4743573 | 0.70 | — | — | |
| SCHEMBL967625 | 0.70 | — | — | |
| SCHEMBL965907 | 0.70 | — | — | |
| SCHEMBL2164003 | 0.67 | — | — | |
| SCHEMBL13240549 | 0.67 | KDM4C (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1888082-B1 | MOTILIDE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2012-09-12 | — | — | EP | disclosed |
| US-7582611-B2 | Treating disorders of gastric motility; decreasing side effects of erythromycin A | PFIZER INC. (US) | 2009-09-01 | — | — | US | disclosed |
| EP-1888082-A4 | MOTILIDE COMPOUNDS | PFIZER (US) | 2008-12-17 | — | — | EP | disclosed |
| EP-1888082-A1 | MOTILIDE COMPOUNDS | Pfizer, Inc. (US) | 2008-02-20 | — | — | EP | disclosed |
| WO-2006127252-A1 | MOTILIDE COMPOUNDS | PFIZER, INC. (US) | 2006-11-30 | — | — | WO | disclosed |
| US-20060270616-A1 | Motilide compounds | PFIZER INC. | 2006-11-30 | — | — | US | disclosed |